HomeCompareGWIN vs ABBV

GWIN vs ABBV: Dividend Comparison 2026

GWIN yields 57.14% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GWIN wins by $463.5K in total portfolio value
10 years
GWIN
GWIN
● Live price
57.14%
Share price
$3.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$565.8K
Annual income
$127,359.58
Full GWIN calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GWIN vs ABBV

📍 GWIN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGWINABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GWIN + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GWIN pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GWIN
Annual income on $10K today (after 15% tax)
$4,857.14/yr
After 10yr DRIP, annual income (after tax)
$108,255.64/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GWIN beats the other by $87,199.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GWIN + ABBV for your $10,000?

GWIN: 50%ABBV: 50%
100% ABBV50/50100% GWIN
Portfolio after 10yr
$334.1K
Annual income
$76,065.67/yr
Blended yield
22.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GWIN
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GWIN buys
0
ABBV buys
0
No recent congressional trades found for GWIN or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGWINABBV
Forward yield57.14%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$565.8K$102.3K
Annual income after 10y$127,359.58$24,771.77
Total dividends collected$464.7K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GWIN vs ABBV ($10,000, DRIP)

YearGWIN PortfolioGWIN Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$16,414$5,714.29$11,550$430.00+$4.9KGWIN
2$26,329$8,765.97$13,472$627.96+$12.9KGWIN
3$41,313$13,141.14$15,906$926.08+$25.4KGWIN
4$63,476$19,270.90$19,071$1,382.55+$44.4KGWIN
5$95,591$27,671.86$23,302$2,095.81+$72.3KGWIN
6$141,229$38,945.95$29,150$3,237.93+$112.1KGWIN
7$204,890$53,775.28$37,536$5,121.41+$167.4KGWIN
8$292,144$72,911.59$50,079$8,338.38+$242.1KGWIN
9$409,754$97,160.29$69,753$14,065.80+$340.0KGWIN
10$565,797$127,359.58$102,337$24,771.77+$463.5KGWIN

GWIN vs ABBV: Complete Analysis 2026

GWINStock

Glorywin Entertainment Group, Inc. engages in the provision of junket services and information technology infrastructure for land-based casinos in Cambodia. It also provides technical support services. The company was incorporated in 2010 and is based in Macau.

Full GWIN Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GWIN vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GWIN vs SCHDGWIN vs JEPIGWIN vs OGWIN vs KOGWIN vs MAINGWIN vs JNJGWIN vs MRKGWIN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.